28.94

2.55% 0.72

Pre-market: 29.51 0.57 +1.97%

Neurogene Inc (NGNE)

Overview News Price History Financials Discussions Forecast

Neurogene Inc stock is traded at $28.94, with a volume of 143.30K. It is up +2.55% in the last 24 hours and up +39.87% over the past month. Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Previous Close:

$28.22

Open:

$28.58

24h Volume:

143.30K

Relative Volume:

0.85

Market Cap:

$451.92M

Revenue:

$925.00K

Net Income/Loss:

$-90.35M

P/E Ratio:

-6.1432

EPS:

-4.7109

Net Cash Flow:

$-78.52M

1W Performance:

+5.43%

1M Performance:

+39.87%

6M Performance:

+4.40%

1Y Performance:

+91.53%

1-Day Range:

$27.46

$29.16

1-Week Range:

$24.88

$29.16

52-Week Range:

$11.77

$37.27

Neurogene Inc Stock (NGNE) Company Profile

Name

Neurogene Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

(877) 237-5020

Address

535 W 24TH STREET, NEW YORK

Employee

131

Twitter

Next Earnings Date

2026-05-08

Latest SEC Filings

NGNE's Discussions on Twitter

Compare NGNE vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NGNE Neurogene Inc	28.94	451.92M	925.00K	-90.35M	-78.52M	-4.7109
VRTX Vertex Pharmaceuticals Inc	424.36	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.06B	5.36B	287.73M	924.18M	2.5229

Neurogene Inc Stock (NGNE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-17-25	Initiated	Craig Hallum	Buy
May-16-25	Downgrade	Robert W. Baird	Outperform → Neutral
Jun-27-24	Initiated	BMO Capital Markets	Outperform
Jun-11-24	Initiated	Robert W. Baird	Outperform
Apr-29-24	Initiated	Leerink Partners	Outperform
Mar-21-24	Initiated	William Blair	Outperform
Jan-08-24	Initiated	H.C. Wainwright	Buy
Jan-05-24	Initiated	Stifel	Buy
Jan-04-24	Initiated	TD Cowen	Outperform

View All

Neurogene Inc Stock (NGNE) Latest News

May 05, 2026

We Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business Growth - Yahoo Finance

May 05, 2026

May 03, 2026

Jennison Associates LLC Increases Holdings in Neurogene Inc. $NGNE - MarketBeat

May 03, 2026

Apr 30, 2026

Neurogene (NGNE) Expected to Announce Quarterly Earnings on Thursday - MarketBeat

Apr 30, 2026

Apr 28, 2026

ICV delivery approach for CNS gene therapy set for American Society of Gene and Cell Therapy meeting, Neurogene Inc. - Traders Union

Apr 28, 2026

Guggenheim reiterates Neurogene stock rating with $69 target By Investing.com - Investing.com Australia

Apr 28, 2026

Guggenheim Initiates Neurogene(NGNE.US) With Buy Rating, Announces Target Price $69 - Moomoo

Apr 28, 2026

Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy - ChartMill

Apr 28, 2026

Guggenheim reiterates Neurogene stock rating with $69 target - Investing.com

Apr 28, 2026

Apr 22, 2026

NGNE Neurogene posts narrower Q4 2025 loss than consensus estimates, edges down modestly in today’s trading. - Cổng thông tin điện tử tỉnh Lào Cai

Apr 22, 2026

Apr 20, 2026

Neurogene (NGNE) Chief Commercial Officer listed in new Form 3 - Stock Titan

Apr 20, 2026

Neurogene names commercial chief, adds board member By Investing.com - Investing.com Australia

Apr 20, 2026

Neurogene (NGNE) Stock: Is It Showing Downtrend Signals (Bullish Sentiment) 2026-04-20Top Breakouts - Xã Thanh Hà

Apr 20, 2026

Neurogene appoints Christy Shafer as CCO - The Pharma Letter

Apr 20, 2026

Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail to Board of Directors; Advances NGN-401 Gene Therapy for Rett Syndrome - Minichart

Apr 20, 2026

Neurogene names commercial chief, adds board member - Investing.com

Apr 20, 2026

Neurogene Expands Leadership Team to Drive NGN-401 Commercialization - TipRanks

Apr 20, 2026

Neurogene appoints Christy Shafer as chief commercial officer and Christine Mikail, J.D., to board of directors - marketscreener.com

Apr 20, 2026

Neurogene Inc. appoints Christy Shafer as Chief Commercial Officer and adds Christine Mikail to board - Traders Union

Apr 20, 2026

New CCO and board role strengthen Neurogene (NASDAQ: NGNE) leadership - Stock Titan

Apr 20, 2026

Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors - marketscreener.com

Apr 20, 2026

Companies Like Neurogene (NASDAQ:NGNE) Are In A Position To Invest In Growth - simplywall.st

Apr 20, 2026

Apr 16, 2026

[ARS] Neurogene Inc. SEC Filing - Stock Titan

Apr 16, 2026

Neurogene (NASDAQ: NGNE) 2026 proxy sets director, pay and auditor votes - Stock Titan

Apr 16, 2026